{
  "id": 18511153,
  "title": "MucoLife Therapeutics secures €91K from Vinnova to scale manufacturing of COPD treatment",
  "url": "https://urgent.news/2026/11/06/mucolife-therapeutics-secures-91k-from-vinnova-to-scale-manufacturing",
  "topic": "business",
  "section": "Business",
  "published": "2026-11-06T13:58:44.000Z",
  "source": {
    "name": "Tech.eu",
    "slug": "tech-eu",
    "url": "https://tech.eu/2026/11/06/mucolife-therapeutics-secures-91k-from-vinnova-to-scale-manufacturing-of-copd-treatment/"
  },
  "original_language": "en",
  "account": "MucoLife Therapeutics has secured funding from Sweden's innovation agency, Vinnova, for the development of a scalable manufacturing process for MLT-001, a peptide designed to treat chronic obstructive pulmonary disease (COPD). The €91,000 (SEK 1 million) grant will be used to establish a purification process for MLT-001, which is the company's first-in-class inhaled treatment targeting mucus plugging in COPD patients. Mucus obstruction is a significant issue for more than half of moderate-to-severe COPD patients, leading to poor outcomes such as reduced lung function, frequent exacerbations, and increased mortality. MucoLife's work has demonstrated the scalability of MLT-001 synthesis, and the grant will help develop a process that achieves a suitable level of purity and documented yield. The project will also involve collaboration with a contract development and manufacturing organisation (CDMO) partner, aiming to create a process description and control strategy for potential Good Manufacturing Practice (GMP) manufacture. MucoLife's CEO, Thaher Pelaseyed, emphasizes that manufacturing is crucial for transforming a promising molecule into a medicine. With Vinnova's support, MucoLife aims to progress towards clinical trials.",
  "summary": "MucoLife Therapeutics has received €91,000 (SEK 1 million) from Vinnova, Sweden’s innovation agency, through the call “Support to small and medium-sized companies for the use of life science infrastru...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}